Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Stöckle

Showing results (1-10 of 173) with videos related to

Pageof 18
Sort By:
European Urology|June 26, 2007
Editorial comment on: tension and energy-free robotic-assisted laparoscopic radical prostatectomy with interfascial dissection of the neurovascular bundleMichael Stöckle
Der Urologe. Ausg. A|September 27, 2020
[Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit?]Michael Stöckle
Urologie (Heidelberg, Germany)|October 12, 2023
[Cystectomy versus trimodal therapy for bladder cancer]Michael Stöckle
European Urology|September 5, 2022
Re: Tranexamic Acid in Patients Undergoing Noncardiac SurgeryMichael Stöckle
European Urology|April 6, 2019
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-upMichael Stöckle
The Journal of Urology|February 8, 2024
Editorial CommentJulia Heinzelbecker, Michael Stöckle
Der Urologe. Ausg. A|January 19, 2020
[Kidney transplantation and organ donation]Paolo Fornara, Michael Stöckle
European Urology|November 4, 2017
Re: Follow-up of Prostatectomy Versus Observation for Early Prostate CancerJulia Heinzelbecker, Michael Stöckle
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 24, 2012
[Localised prostate cancer: the PREFERE trial]Michael Stöckle, Roswitha Bussar-Maatz
European Urology|September 1, 2015
Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015;16:76-86Carsten-Henning Ohlmann, Michael Stöckle
Pageof 18

Showing results (1-10 of 173) with videos related to

Sort By:
Pageof 18
European Urology|June 26, 2007
Editorial comment on: tension and energy-free robotic-assisted laparoscopic radical prostatectomy with interfascial dissection of the neurovascular bundleMichael Stöckle
Der Urologe. Ausg. A|September 27, 2020
[Neoadjuvant chemohormonal therapy prior to prostatectomy in high-risk prostate cancer-is biochemical recurrence an adequate surrogate marker for clinical benefit?]Michael Stöckle
Urologie (Heidelberg, Germany)|October 12, 2023
[Cystectomy versus trimodal therapy for bladder cancer]Michael Stöckle
European Urology|September 5, 2022
Re: Tranexamic Acid in Patients Undergoing Noncardiac SurgeryMichael Stöckle
European Urology|April 6, 2019
Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-upMichael Stöckle
The Journal of Urology|February 8, 2024
Editorial CommentJulia Heinzelbecker, Michael Stöckle
Der Urologe. Ausg. A|January 19, 2020
[Kidney transplantation and organ donation]Paolo Fornara, Michael Stöckle
European Urology|November 4, 2017
Re: Follow-up of Prostatectomy Versus Observation for Early Prostate CancerJulia Heinzelbecker, Michael Stöckle
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 24, 2012
[Localised prostate cancer: the PREFERE trial]Michael Stöckle, Roswitha Bussar-Maatz
European Urology|September 1, 2015
Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015;16:76-86Carsten-Henning Ohlmann, Michael Stöckle
Pageof 18